findmyKOL
Clinical trialNCT06479863RecruitingEarly phase 1Interventional

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

SponsorAustin Neuromuscular CenterEnrollment10Idiopathic Inflammatory MyopathiesSporadic Inclusion Body Myositis (sIBM)
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

To evaluate the efficacy of Pozelimab/Cemdisiran combination therapy in patients with sIBM
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Austin Neuromuscular Center

    Austin, Texas, United States

    Recruiting
  • Austin Neuromuscular Center

    Austin, Texas, United States

    Yessar hussain, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
8 Aug 2024
Primary completion
30 May 2027
Completion
30 Aug 2027
Last update posted
16 Jan 2026
Registered enrollment
10
Registry id
NCT06479863
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.